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Abstract
This short review outlines the rationale, challenges, and opportunities for intranasal
acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the
development of a therapeutically viable formulation. In vivo testing confirmed achievement of
therapeutically relevant drug levels that matched or exceeded those for oral dosing, with a dramatic
reduction in undesired emetic responses. Intranasal drug delivery is an effective option for the
treatment of Alzheimer's disease and other central nervous system disorders.
Introduction
Intranasal (IN) delivery provides a viable and attractive
option for administering various therapeutic agents [1].
Advantages of IN administration include a large surface
area for delivery, rapid achievement of target drug levels,
and avoidance of first pass metabolism; furthermore, this
delivery route is noninvasive, maximizing patient comfort
and compliance. In addition, IN dosing may facilitate
transport of central nervous system (CNS) drugs into the
brain [2-9], although this concept has not been univer-
sally established [10-14] and may depend on physico-
chemical properties of the drug [15-17]. Examples in the
literature of CNS-related drugs given intranasally include
opioids [18], benzodiazepines [19] and antimuscarinic
agents [20], as well as acetylcholinesterase inhibitors
[10,21-23].
Acetylcholinesterase inhibitors for Alzheimer's 
disease
Acetylcholinesterase activity and inhibition have been the
subject of studies for two decades, since the emergence of
the cholinergic hypothesis, wherein deficits in learning,
memory, and behavior are deemed to be associated with
loss of cholinergic neurotransmission in the hippocam-
pus and cortex [24]. Although various promising new
therapeutic options are being vigorously pursued [25],
acetylcholinesterase inhibitors remain the current front-
line therapeutic approach to treatment of mild-to-moder-
ate Alzheimer's disease (AD) [24,26]. AD is the most com-
mon form of disabling cognitive impairment in the
elderly, and its increasing prevalence reflects a growing
elderly population [27].
Examples of acetylcholinesterases used to treat AD include
taurcine, rivastigmine, donepazil, and galantamine.
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Tacrine was the first acetylcholinesterase inhibitor
approved for AD treatment [28], but this agent has been
associated with some severe side effects, including hepato-
toxicity, necessitating the research and development of
newer inhibitors with greater specificity and higher
potency. At present, commonly administered acetylcho-
linesterase inhibitors include rivastigmine, donepazil,
and galantamine. Among these, galantamine possesses
the dual mechanism of acetylcholinesterase inhibition
and allosteric modulation of nicotinic acetylcholine
receptors [29].
Rationale for intranasal delivery of 
acetylcholinesterase inhibitors
Currently marketed acetylcholinesterase inhibitors are
found entirely in oral dosage form. However, alternative
routes, in particular IN administration, may provide ben-
efits relative to oral dosing. For instance, the relatively low
bioavailability of oral tacrine [30] has generated interest
in delivery via various epithelial tissues, including the
nasal route [31]. Similarly, the oral efficacy of physostig-
mine is limited because of low bioavailability, and inves-
tigations have focused on IN [10,21] and transdermal [32]
delivery as alternatives to intravenous infusion. Transder-
mal physostigmine provides a mean absolute bioavaila-
bility of 36% as compared with only 3% for oral delivery
in humans [32], and IN physostigmine may provide
essentially complete bioavailability [21].
In addition to the avoidance of first pass metabolism, IN
dosing also provides the potential for ameliorating
adverse effects specific to the gastrointestinal (GI) tract. In
the case of galantamine, GI-related side effects (for exam-
ple, nausea and vomiting) are the adverse events that most
commonly lead to discontinuation of treatment [33].
Moreover, the impact of galantamine on evacuative func-
tions when it comes into contact with intestinal tissue has
been described both in vivo and in vitro [34].
Development of intranasal galantamine
Because of solubility and dose volume limitations, the
commercially available form of galantamine, namely the
hydrobromide salt, is not suitable for IN dosing. There-
fore, an alternative drug formulation with a different,
pharmaceutically acceptable counter cation, lactate, was
developed [22]. The performance of galantamine-hydro-
bromide and galantamine-lactate was monitored using an
in vitro epithelial tissue model and associated analyses
[35]. Based on its increased solubility, low cytotoxicity,
and high cell viability in vitro, galantamine-lactate repre-
sents a viable candidate for IN delivery.
Having developed a strategy to suitably increase the con-
centration of galantamine for IN delivery, the next step
was to optimize its transepithelial permeation while
retaining low toxicity [23]. Employing the same in vitro
epithelial tissue model, various formulations containing
permeation enhancers were screened via a design-of-
experiments approach. Data collected during the in vitro
screening phase included permeation, cytotoxicity, cell
viability, and transepithelial electrical resistance (TER).
The latter findings represent the integrity of the tight junc-
tions between epithelial cells; reduction in TER corre-
sponds with increased potential for paracellular, and
hence overall, drug permeation. An optimal formulation
was identified with low cytotoxicity, high cell viability,
reduced TER, and enhanced permeation in vitro.
Various formulations were tested in vivo in rat [22,23].
There was a good correlation between the in vitro permea-
tion rate and in vivo drug levels achieved, validating the
utility of the epithelial tissue model. In the absence of per-
meation enhancers, the absolute oral and nasal bioavaila-
bility was approximately 22% to 23%; the incorporation
of permeation enhancers approximately doubled the IN
bioavailability (41%).
Intranasal galantamine alleviates GI-related side 
effects.
In order to explore the hypothesis that IN dosing reduces
GI-related side effects when compared with oral dosing,
emetic responses were monitored for the oral versus IN
galantamine formulations in a ferret model. The ferret was
previously established to be a good model for emetic sen-
sitivity [36]. The emetic study revealed a dramatic
decrease in GI-related side effects when galantamine was
administered by the IN route. During the first 4 hours
after IN administration, only three emeses (retching
events) were observed as compared with 34 with oral
administration. The near absence of nausea, achieved
despite similar or higher systemic exposure due to IN
administration, further confirms that the observed emetic
side effects associated with oral galantamine are caused by
interactions in the GI tract and not systemic exposure to
the drug.
Conclusion
As shown using IN galantamine, IN delivery provides a
viable and attractive option for administering various
therapeutic drugs. An in vitro screening model facilitated
the development of a therapeutically viable formulation,
whereas in vivo testing confirmed achievement of thera-
peutically relevant drug levels that matched or exceeded
those for oral dosing, with a dramatic reduction in unde-
sired emetic responses. The screening methods used show
that IN drug delivery is an effective option for the treat-
ment of AD and other CNS disorders.BMC Neuroscience 2008, 9(Suppl 3):S6 http://www.biomedcentral.com/1471-2202/9/S3/S6
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